Findings

What do systematic reviews say?

12 questions · 12 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 50%GRADE not reported 0 · 0%Very low 1 · 8.3%Low 4 · 33.3%Moderate 1 · 8.3%High 0 · 0%

Cytisine vs nicotine replacement therapy

Smoking abstinence at longest · people who smoke

Cytisine may leads to higher smoking abstinence at longest compared with nicotine replacement therapy (low certainty).

1 finding from 1 review

Nicotine receptor partial agonists for smoking cessation 2023 · Cochrane Headline outcomes only
RR 1.43 [1.13, 1.8]
1 study · 1310 participants
Low

Cytisine vs nicotine replacement therapy

SAEs · people who smoke

It is very uncertain whether cytisine changes SAEs compared with nicotine replacement therapy (very low certainty).

1 finding from 1 review

Nicotine receptor partial agonists for smoking cessation 2023 · Cochrane Headline outcomes only
RR 1.15 [0.76, 1.75]
1 study · 1310 participants
Very low

Cytisine vs nicotine replacement therapy

Neuropsychiatric SAEs · people who smoke

The review found no eligible studies for this question.

1 finding from 1 review

Nicotine receptor partial agonists for smoking cessation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cytisine vs nicotine replacement therapy

Cardiac SAEs · people who smoke

The review found no eligible studies for this question.

1 finding from 1 review

Nicotine receptor partial agonists for smoking cessation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cytisine vs varenicline

SAEs · people who smoke

Cytisine showed no clear difference in SAEs compared with varenicline (low certainty).

1 finding from 1 review

Nicotine receptor partial agonists for smoking cessation 2023 · Cochrane Headline outcomes only
RR 0.67 [0.44, 1.03]
2 studies · 2017 participants
Low

Cytisine vs varenicline

Neuropsychiatric SAEs · people who smoke

The review found no eligible studies for this question.

1 finding from 1 review

Nicotine receptor partial agonists for smoking cessation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cytisine vs varenicline

Cardiac SAEs · people who smoke

The review found no eligible studies for this question.

1 finding from 1 review

Nicotine receptor partial agonists for smoking cessation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cytisine vs placebo or no medication

Smoking abstinence at longest · people who smoke

Cytisine probably leads to higher smoking abstinence at longest compared with placebo or no medication (moderate certainty).

1 finding from 1 review

Nicotine receptor partial agonists for smoking cessation 2023 · Cochrane Headline outcomes only
RR 1.3 [1.15, 1.47]
4 studies · 4623 participants
Moderate

Cytisine vs placebo or no medication

SAEs · people who smoke

Cytisine showed no clear difference in SAEs (cytisine vs placebo or no medication) compared with placebo or no medication (low certainty).

1 finding from 1 review

Nicotine receptor partial agonists for smoking cessation 2023 · Cochrane Headline outcomes only
RR 1.04 [0.78, 1.37]
3 studies · 3781 participants
Low

Cytisine vs placebo or no medication

Neuropsychiatric SAEs · people who smoke

The review found no eligible studies for this question.

1 finding from 1 review

Nicotine receptor partial agonists for smoking cessation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cytisine vs placebo or no medication

Cardiac SAEs · people who smoke

The review found no eligible studies for this question.

1 finding from 1 review

Nicotine receptor partial agonists for smoking cessation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cytisine vs varenicline

Smoking abstinence at longest · people who smoke

Cytisine showed no clear difference in smoking abstinence at longest compared with varenicline (low certainty).

1 finding from 1 review

Nicotine receptor partial agonists for smoking cessation 2023 · Cochrane Headline outcomes only
RR 1 [0.79, 1.26]
2 studies · 2131 participants
Low